Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis (PET-NAVIE)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4G5
- Not yet recruiting
- University Institute of Cardiology and Respirology of Quebec
-
Contact:
- Jean-Francois Sarrazin
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
Contact:
- Gad Abikhzer
- Phone Number: 514-340-8222
- Email: gad101@hotmail.com
-
Montreal, Quebec, Canada, H4A 3J1
- Not yet recruiting
- McGill University Health Center
-
Contact:
- Anthony Ciarallo
- Phone Number: 514-934-1934
- Email: Anthony.Ciarallo.med@ssss.gouv.qc.ca
-
Montréal, Quebec, Canada, H2X 3E4
- Not yet recruiting
- Centre Hospitalier de l'Université de Montréal
-
Contact:
- Daniel Juneau
-
Montréal, Quebec, Canada, H3l 3c1
- Recruiting
- Montreal Heart Institute
-
Contact:
- Matthieu Pelletier-Galarneau
- Phone Number: 4418 5143763330
- Email: matthieu.pelletier-galarneau@icm-mhi.org
-
Sherbrooke, Quebec, Canada, J1H5H3
- Not yet recruiting
- Centre Hospitalier de l'Université de Sherbrooke
-
Contact:
- Etienne Rousseau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years of age or older, capable to provide informed consent;
- Referred for a FDG-PET/CT study
- Classified as having Possible IE prior to FDG-PET/CT imaging;
- Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.
Exclusion Criteria:
- Subjects with prosthetic cardiac valve and/or CIED;
- Pregnant or breastfeeding female;
- Body mass index > 45 kg/m2.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with suspected native valve endocarditis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with Possible IE that will be appropriately reclassified
Time Frame: 3 months
|
Proportion of patients with Possible IE that will be appropriately reclassified as Definite IE by the addition of FDG-PET to the Duke criteria.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sensitivity, specificity, and accuracy of FDG-PET for the detection of NVE
Time Frame: 3 months
|
3 months
|
|
Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVESensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVE
Time Frame: 3 months
|
3 months
|
|
Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET but excluding TEE for the detection of NVE
Time Frame: 3 months
|
3 months
|
|
Differences in maximal standardized uptake value (SUVmax) between infected and non-infected valves
Time Frame: 3 months
|
3 months
|
|
Differences target-to-background ratio (TBR) between infected and non-infected valves
Time Frame: 3 months
|
3 months
|
|
Proportion of patients in whom a TEE was not necessary to diagnose NVE through the addition of FDG-PET
Time Frame: 3 months
|
3 months
|
|
Proportion of patients with final diagnosis of IE with septic emboli detected on whole body FDGPET
Time Frame: 3 months
|
3 months
|
|
Differences in the rate of sub-optimal suppression protocol between males and females
Time Frame: 3 months
|
3 months
|
|
Proportion of patients with incidental cancer identified on FDG-PET
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between the diagnostic accuracy and available demographic, technical, and clinical factors
Time Frame: 3 months
|
Correlation between the diagnostic accuracy (false-negative/false-positive studies versus truenegative/true-positive) and the available demographic and clinical factors (age, sex, duration of antibiotherapy, blood glucose, CRP, history of renal failure, history of malignancy, history of diabetes, chronic liver disease, time since onset of symptoms, and quality of myocardial suppression) as well as camera system (analog vs digital)
|
3 months
|
|
Difference in the area under the curve (c-statistic) of the Duke criteria with TEE but excluding FDG-PET, with TEE and FDG-PET, and with FDG-PET but excluding TEE
Time Frame: 3 months
|
3 months
|
|
|
Differences in sensitivity, specificity, and accuracy of FDG-PET with and without respiratory and ECG-gated acquisitions
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MP-33-2020-2674
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.